Celiac Disease Treatment Market To Grow More than TenFold To $551M By 2023, Says GlobalData

The celiac disease treatment market value will expand more than tenfold from an estimated $49.6M in 2013 to $551.1M by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%, according to research and consulting firm GlobalData.

The company’s latest report^* states that the US will continue to account for almost all of the celiac disease therapeutics space, which also includes the five European countries (5EU) of France, Germany, Spain, Italy and the UK. The US share will slip slightly from 99% in 2013 to just under 98% by the end of the forecast period.

Abhilok Garg, Ph.D., GlobalData’s Analyst covering Immunology, says that the market will be driven primarily by the potential introduction of two novel pipeline drugs, Alba/Teva’s larazotide acetate and Alvine/AbbVie’s latiglutenase, which are designed to be used as adjunctive treatments to the current standard of care, a Gluten-Free Diet (GFD).

Garg comments: “Larazotide acetate is forecast to launch in the US in Q1 2018, with the key competitive advantage of targeting the majority of the disease population, compared with the 4–7% of refractory patients, who are currently treated with generics including steroids and immunosuppressants.

“In Q1 2019, larazotide acetate is expected to launch in the 5EU, while latiglutenase may potentially launch in the US. These pipeline drugs are forecast to increase sales in the six major markets (6MM) from $49.6M in 2013 to $289.9M by the end of 2019.”

Garg adds that Q1 2020 may see the launch of latiglutenase in the 5EU, thereby boosting the 6MM sales further to $343.3M, with a steady incline up to $551.1M by 2023.

Despite the anticipated impact of these novel drugs, there are a number of barriers to growth in the celiac disease treatment market, such as limited physician and patient awareness of the condition and a lack of confidence in pipeline drugs compared with a GFD.

Garg continues: “Improved physician education concerning GFDs and developments in the gluten-free food market may refine the standard of care and this, in turn, may deter physicians from prescribing adjunctive treatments.”

*Opportunity Analyzer: Celiac Disease - Opportunity Analysis and Forecast to 2018

This report provides annualized celiac disease therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018 and ten years to 2023 in the US and five major European markets (Germany, France, Spain, Italy and the UK). Key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, pipeline analysis and clinical trial design.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

About Globaldata
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.